
YMTX
Healthcare · Biotechnology · $20.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2022 | Before the open | -1.08 | -2.17 | -100.9% |
| Aug 4, 2022 | After the close | -0.99 | -3.15 | -218.2% |
| May 12, 2022 | After the close | -0.95 | -6.16 | -548.4% |
| Mar 24, 2022 | After the close | -1.05 | -7.00 | -566.7% |
| Nov 15, 2021 | Before the open | -1.13 | -6.79 | -500.9% |
| Aug 12, 2021 | After the close | -0.84 | -7.21 | -758.3% |
| May 17, 2021 | After the close | -0.83 | -5.95 | -616.9% |
| Mar 31, 2021 | Before the open | -2.80 | 27.72 | +1090.0% |
| Nov 16, 2020 | After the close | -3.60 | -2.20 | +38.9% |
| Aug 6, 2020 | After the close | -4.25 | -3.40 | +20.0% |
| May 15, 2020 | After the close | -5.10 | -3.80 | +25.5% |
| Mar 10, 2020 | After the close | -5.75 | -4.60 | +20.0% |
| Nov 7, 2019 | After the close | -8.10 |
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and…
| -5.00 |
| +38.3% |
| Aug 7, 2019 | After the close | -7.53 | -7.80 | -3.6% |
| May 8, 2019 | After the close | -7.85 | -5.60 | +28.7% |
| Mar 8, 2019 | After the close | -8.50 | -7.20 | +15.3% |
| Nov 6, 2018 | After the close | -0.44 | -0.50 | -13.6% |
| Aug 8, 2018 | After the close | -0.39 | -0.43 | -10.3% |
| May 9, 2018 | After the close | -0.53 | -0.32 | +39.6% |
| Mar 14, 2018 | After the close | -0.64 | -0.51 | +20.3% |